Selected article for: "acute respiratory infection and China Hubei province"
Author: Li, Hongyan; Lu, Wanting; Li, Yinyin; Lu, Yinying; Li, Fei
Title: Reviewing immunopathology characteristics of SARS-CoV-2 for cancer entwisted with SARS-CoV-2
  • Cord-id: pciglpuv
  • Document date: 2021_1_27
    • ID: pciglpuv
    Snippet: In December 2019, the outbreak of a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), infection that started in Wuhan, Hubei Province, China, has spread to all world. Based on the accumulated data and knowledge on the coronavirus infection and immunology characteristics, this review would hope to give some hints on human immune response to SARS-CoV-2 infection in cancer patients. This insight may help in designing the appropriate immune intervention for treatment a
    Document: In December 2019, the outbreak of a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), infection that started in Wuhan, Hubei Province, China, has spread to all world. Based on the accumulated data and knowledge on the coronavirus infection and immunology characteristics, this review would hope to give some hints on human immune response to SARS-CoV-2 infection in cancer patients. This insight may help in designing the appropriate immune intervention for treatment and the prophylactic/therapeutic methods against cancer under current coronavirus from immunopathology characteristics of SARS-CoV-2 and cancer entwisted with it. We should achieve accurate diagnosis and treatment for cancer patients through advantages of multidisciplinary diagnosis and treatment team. It is believed that we will eventually overcome the epidemic and win in the future.

    Search related documents:
    Co phrase search for related documents
    • accurate diagnosis and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • accurate diagnosis and adjuvant chemotherapy: 1
    • accurate diagnosis and long period: 1, 2
    • acute ards respiratory distress syndrome and adjuvant therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute ards respiratory distress syndrome and liver lymph: 1
    • acute ards respiratory distress syndrome and liver lymph specific: 1
    • acute ards respiratory distress syndrome and long period: 1, 2
    • acute sars cov respiratory syndrome coronavirus and adjuvant therapeutic drug: 1
    • acute sars cov respiratory syndrome coronavirus and adjuvant therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • acute sars cov respiratory syndrome coronavirus and liver lymph: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute sars cov respiratory syndrome coronavirus and liver lymph specific: 1, 2
    • acute sars cov respiratory syndrome coronavirus and long period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and long term induction: 1
    • acute sars cov respiratory syndrome coronavirus and low immune function: 1, 2
    • adjuvant therapy and long period: 1